Highlights of the North American Cystic Fibrosis Conference 2011.
Royal Brompton & Harefield NHS Trust, London & Imperial College London, UK.
Rishi
R
Pabary
Rebecca
R
Thursfield
Jane C
JC
Davies
D000293:Adolescent; D000328:Adult; D000627:Aminophenols / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003226:Congresses as Topic; D003550:Cystic Fibrosis / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000187:drug effects* / Q000235:genetics*; D004195:Disease Models, Animal; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D015997:Neonatal Screening / Q000458:organization & administration; D010069:Oxadiazoles / Q000494:pharmacology / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011379:Prognosis; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D055815:Young Adult
D000627:Aminophenols; D000900:Anti-Bacterial Agents; D015507:Drugs, Investigational; D010069:Oxadiazoles; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor; C515878:ataluren